Study of Biological Markers in Children With Sickle Cell Disease

Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)

Sickle cell disease is associated with significant morbi-mortality hence the interest in an early and targeted care. At present, there is no plasmatic marker able to identify infants at higher risk of developping severe complications later in life. However, recent studies have demonstrated a correlation between certain complications of the disease and biomarkers of the endothelial dysfunction characterizing it.

Investigators prospectively followed a cohort of children diagnosed with SCD through the universal neonatal screening using inflammatory and haemostatic plasmatic markers to study their annual evolution. Investigators then will evaluate potential associations between these biological markers and the occurrence of SCD related complications. A secondary objective of this study is to evaluate the repercussions of therapeutic intervention on these markers.

.

Inclusion Criteria:

• Patient aged less than 6 months
• Sickle cell syndrome SS, Sβthal or SC confirmed by hemoglobin electrophoresis
• Subjects legal representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to let participate their child in the study

Exclusion Criteria:

• Congenital abnormality other than sickle cell disease except for a glucose-6-phosphate-deshydrogenase
• Prematurity
• Initiation of the following therapies before enrollment: chronic transfusion regimen or bone marrow transplantation